uniq pinp ria 67034 - rezultati pretrage

Australija - engleski - Department of Health (Therapeutic Goods Administration)

dbl vincristine sulfate 2mg/2ml injection vial

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australija - engleski - Department of Health (Therapeutic Goods Administration)

dbl vincristine sulfate 1mg/1ml injection vial

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Singapur - engleski - HSA (Health Sciences Authority)

teleflex lma unique™

teleflex medical asia pte. ltd. - anaesthesiology - lma unique™ is indicated for use as an alternative to the face mask for achieving and maintaining control of the airway during routine and emergency anaesthetic procedures in fasted patients. it is also indicated for securing the immediate airway in known or unexpected difficult airway situations. it is provided sterile.

Singapur - engleski - HSA (Health Sciences Authority)

teleflex lma unique™ (silicone cuff)

teleflex medical asia pte. ltd. - anaesthesiology - the lma® unique™ (silicone cuff) and lma® unique™ (silicone cuff) cuff pilot™ are indicated for use in achieving and maintaining control of the airway during routine and emergency aesthetic procedures in fasted patients using either spontaneous or positive pressure ventilation (ppv).

Singapur - engleski - HSA (Health Sciences Authority)

teleflex lma unique™ (silicone cuff) cuff pilot laryngeal mask airway

teleflex medical asia pte. ltd. - anaesthesiology - lma® unique™ (silicone cuff) cuff pilot™ is indicated for use in achieving and maintaining control of the airway during routine and emergency anaesthetic procedures in fasted patients using either spontaneous or positive pressure ventilation (ppv). they are also indicated for securing the immediate airway in known or unexpected difficult airway situations. they are best suited for use in elective surgical procedures where tracheal intubation is not necessary. they may be use to establish an immediate, clear airway during cardiopulmonary resuscitation (cpr) in the profoundly unconscious patient with absent glossopharyngeal and laryngeal reflexes requiring artificial ventilation. in these cases, the devices should be used only when tracheal intubation is not possible.